ImpriMed Korea

Find the best drugs for treating cancer
BEFORE treatment begins

We use functional assays and artificial intelligence to provide personalized predictions on survival and response.

Technology

We analyze traits of each patient’s cancer cells to predict his or her survival and response specific to the choice of chemotherapeutic regimen. The predictive information can help to identify an optimal treatment for each patient.  

Human Oncology Pipeline

Precision medicine services for individual blood cancer patients and CRO services for pharmaceutical companies screening a successful drug candidate

STAGE
R&D
COMMERCIAL
R&D
COMMERCIAL
Service
Indication/Type
Tech Development
Clinical Study
Innovative Tech Approval
Approval
Sales
IMK-NL-1
Non-Hodgkin lymphoma treatment selection
IMK-MM-1
Multiple myeloma (MM) treatment selection
IMK-AML-1
Acute myeloid leukemia treatment selection
IMK-DS
Antibody drug conjugates screening and ex vivo efficacy test
IMK-NL-1
Non-Hodgkin lymphoma treatment selection
IMK-MM-1
Multiple myeloma (MM) treatment selection
IMK-AML-1
Acute myeloid leukemia treatment selection
IMK-DS
Antibody drug conjugates screening and ex vivo efficacy test
IMK-NL-1
Non-Hodgkin lymphoma treatment selection
IMK-MM-1
Multiple myeloma (MM) treatment selection
IMK-AML-1
Acute myeloid leukemia treatment selection
IMK-DS
Antibody drug conjugates screening and ex vivo efficacy test
Current
Plan by Q3 of 2024
Personalized Prediction Profile provides detailed information about your dog's cancer cells and predictions on response to anticancer drugs
Coming Soon – Early 2023

Personalized Prediction Profile for Canine Lymphoma and Leukemia

We measure how your dog's live cancer cells respond to different anticancer drugs. Then we use artificial intelligence (AI) to combine these measurements with other biological information to predict which drugs are most likely to be effective for your dog's lymphoma or leukemia.

Our mission is to empower clinicians and help patients with the best predictive information for personalized cancer care.

Our Milestones

2018
  • Opened ImpriMed Korea office
  • Received seed funding
2019
  • Received the Korean Venture Accreditation
  • Admitted to the Seoul Startup Hub
2020
  • Acquired IRB approval for the R&D on precision medicine technology for human blood cancer
  • Received a research grant ($370,000) from the Seoul Business Administration
2021
  • Won 4th place in the AI model development national competition held by the Ministry of Science and ICT in Korea
  • Received the research grant ($280,000) from the National Industry Promotion Agency
  • Nominated as one of the Top 100 Korean AI start-ups
  • Filed 3rd patent titled Predicting Clinical Outcome or Prognosis of Cancer Treatment based on Machine Learning
  • Received a research grant ($80,000) from the National Research Foundation of Korea
2022
  • Signed MOU with The Catholic University Seoul St. Mary's Hospital
  • Selected to the Mayo Clinic Platform Accelerate Program 2022
  • Presenting our AI precision medicine technology for newly diagnosed multiple myeloma patients at the International Myeloma Society 2022
Today
ImpriMed is bringing together our expertise in humans and canines to accelerate the development of AI-driven personalized medicine solutions for all cancer patients.

Our Team

A profile image of Sungwon Lim, CEO & Co-Founder at ImpriMed, Inc.
Co-Founder & CEO
Board Director

Sungwon Lim

A profile image of Jamin Koo, Director & Co-Founder at ImpriMed, Inc.
Co-Founder & Director
Board Director

Jamin Koo

Lead Data Scientist

Gyucheol Choi

Lead Scientist

Kwan Hyun Kim

Business Manager

Hojung Park

Research Associate

Seunghyeok Ham

Research Associate

Seongjoon Lee

Software Engineer

Heeju Choi

Executive Assistant

Jungwoon Bae

Research Assistant

Seseon Park

advisors & board directors

Medical Advisor

Jong Cheol Lee

MD, PhD

GangNeung Asan Hospital

Dept of Otorhinolaryngology

Offices

Join our growing team!

Contact Us

Please fill out the form to get in touch with us.
We’ll get back to you within 1-2 business days.

Email us

General inquiries – imprimedkorea@imprimedicine.com

Let's get in touch

Type of Inquiry *

Your Name *

-

Company *

Your Email *

Phone Number

Contact Preference

How did you hear about us? *

By submitting this form, you agree to receive communications from ImpriMed. Read our Privacy Policy.

Your message has been submitted.
We will get back to you within 24-48 hours.
Oops! Something went wrong.